Related Experiment Video

Updated: Jul 20, 2025

Dissection of the Mouse Pancreas for Histological Analysis and Metabolic Profiling
08:21

Dissection of the Mouse Pancreas for Histological Analysis and Metabolic Profiling

Published on: August 19, 2017

37.0K

Immune vulnerabilities of mutant KRAS in pancreatic cancer

Noah C Cheng1, Robert H Vonderheide1

  • 1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

Trends in Cancer
|July 31, 2023
PubMed

Insights

Targeting mutant Kirsten rat sarcoma (KRAS) gene (mKRAS) offers therapeutic potential. mKRAS is an immunological antigen, and its inhibitors may modulate the tumor microenvironment for cancer therapy.

Area of Science:

  • Oncogenomics
  • Cancer Immunology
  • Drug Discovery

Background:

  • The mutant Kirsten rat sarcoma (KRAS) gene (mKRAS) has been a long-standing therapeutic target.
  • mKRAS plays a significant role in creating an immunosuppressive tumor microenvironment, particularly in pancreatic cancer.
  • mKRAS is recognized as an immunological antigen, a shared neoepitope associated with cancer development.

Purpose of the Study:

  • To explore the therapeutic potential of targeting mKRAS.
  • To investigate the immunological aspects of mKRAS as a therapeutic target.
  • To examine the immune modulatory capabilities of mKRAS inhibitors for combination therapies.

Main Methods:

  • Development and application of small-molecule inhibitors targeting mKRAS.
  • Biochemical and immunological validation of mKRAS as a neoantigen.
  • Analysis of mKRAS peptide processing and presentation by major histocompatibility complex (MHC) in tumors.

Main Results:

  • Emergence of broadly applicable and tumor-specific small-molecule inhibitors for mKRAS.
  • Demonstration of mKRAS as a desirable immunological target.
  • Identification of potential immune modulatory effects of mKRAS inhibitors.
  • Validation of mKRAS peptides as naturally processed and presented antigens in tumors.

Conclusions:

  • Targeting mKRAS therapeutically is becoming a reality with novel small-molecule inhibitors.
  • mKRAS presents a promising target for cancer immunotherapy due to its immunological properties.
  • mKRAS inhibitors hold potential for immune-oncological combination strategies, particularly in pancreatic cancer.
Keywords:
TCR therapiesimmune responseinhibitorsmutant KRASpancreatic cancervaccines

More Related Videos

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture08:16

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture

Published on: February 11, 2019

8.7K
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression09:25

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression

Published on: June 28, 2013

27.0K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.0K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.0K